The global market for polymerase chain reaction (PCR) technologies is projected to grow from $12.5 billion in 2021 to $18.3 billion by 2027, at an impressive compound annual growth rate (CAGR) of 8.0%. Several key factors are driving this robust market expansion.
Firstly, the rising incidence of infectious diseases, genetic disorders, and other targeted conditions is fueling demand for accurate and rapid diagnostic tools like PCR. Additionally, continued innovations in PCR technologies, along with increasing research funding and investments, are propelling the market forward. Moreover, the growing penetration of these technologies in emerging economies presents lucrative opportunities for market players.
However, the high costs associated with digital PCR (dPCR) instruments and certain technical limitations of quantitative PCR (qPCR) and dPCR are potential restraints on market growth during the forecast period.
Download a PDF brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=96291811
Market Dynamics
On the demand side, increasing investments, funds, and grants for research and development (R&D) in genomics and personalized medicine are boosting the adoption of PCR technologies. Government agencies and private organizations worldwide are recognizing the crucial role of qPCR and dPCR products in genomics research, leading to substantial funding initiatives.
Conversely, the high costs of dPCR instruments, which can range from $55,000 to $120,000 in the US, may limit their demand, especially among smaller research organizations and companies.
Emerging Opportunities and Challenges
Emerging markets, particularly in Asia, offer significant growth opportunities for PCR technologies. Rising healthcare expenditures, expanding infrastructure, and increasing awareness about genomic diagnostics in these regions are driving demand. However, the adoption and implementation of guidelines like the Minimum Information for Publication of Quantitative Real-time PCR Experiments (MIQE) remain a challenge, as they involve laborious preparation and considerations.
Market Segmentation
The reagents and consumables segment accounted for the largest share of the PCR technologies market in 2021, driven by the expanding applications of dPCR, increasing analytical procedures, and the rising availability of novel dPCR reagents worldwide.
The qPCR segment held the largest share by technique in 2021, owing to factors such as automation, growing adoption among researchers and healthcare professionals, and increased funding for qPCR-based research.
Geographically, North America dominated the market in 2021, while the Asia-Pacific region is expected to witness the highest CAGR during the forecast period, driven by healthcare infrastructure modernization, increasing penetration of cutting-edge diagnostics, and growing awareness about gene-based disease diagnosis and treatment.
Prominent players in the PCR technologies market include Thermo Fisher Scientific, F. Hoffmann-La Roche, Bio-Rad Laboratories, QIAGEN, Takara Bio, Agilent Technologies, bioMérieux, Fluidigm Corporation, Danaher Corporation, Abbott Laboratories, Merck KGaA, Becton Dickinson and Company, Promega Corporation, Eppendorf AG, and Analytik Jena AG.
In conclusion, the PCR technologies market is poised for substantial growth, driven by increasing disease prevalence, technological advancements, and expanding applications in emerging economies. While challenges exist, the market’s prospects remain promising, fueled by continuous innovation and growing demand for accurate and efficient diagnostic tools.
The global veterinary active pharmaceutical ingredient (API) market is experiencing robust growth, projected to expand from $8.5 billion in 2023 to $11.9 billion by 2028, with a compound annual growth rate (CAGR) of 6.9%. This thriving market is fueled by several factors, including the rising prevalence of transboundary and zoonotic diseases, an increase in the global animal population and pet ownership, and the implementation of improved disease control and prevention measures.
Download a PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=91801752
Growth Drivers:
- Transboundary and Zoonotic Diseases: The growing concern over diseases that can rapidly spread across borders and between animals and humans, such as avian influenza, rabies, and African swine fever, has led to an increased demand for effective veterinary APIs. These APIs are crucial for developing therapeutics that target specific pathogens, reduce symptom severity, and aid in the recovery of infected animals, ultimately reducing the risk of transmission to humans.
- Rising Pet Ownership and Animal Population: As more people adopt pets and the global animal population grows, the demand for veterinary medicines and animal health products has surged. This trend has driven the development of the veterinary API industry, which supplies the active ingredients necessary for these products.
- Improved Disease Control and Prevention: Governments, international organizations, and veterinary professionals are collaborating to develop and implement disease control programs, further fueling the need for quality veterinary APIs. These APIs play a vital role in supporting these programs and minimizing the impact of diseases on public health and global trade.
Market Dynamics:
While the high costs of veterinary diagnostics and treatment pose a restraint, the rising awareness about animal health and welfare presents significant opportunities for the market. Challenges persist in the synthesis of large molecule APIs, such as proteins and peptides, due to their complexity and the need for specialized equipment and techniques.
Regional Insights
North America held the largest market share for veterinary APIs in 2022, driven by factors such as increasing research and development investments in API manufacturing and government support for API manufacturing facilities. However, the Asia-Pacific region is expected to witness substantial growth due to the rising demand for animal health products and the presence of major API manufacturers.
Key Players:
Major players in the veterinary API market include Phibro Animal Health Corporation (US), Fabbrica Italiana Sintetici S.p.A. (Italy), Sequent Scientific Ltd. (India), Excel Industries Ltd. (India), NGL Fine-Chem Ltd. (India), Insulnsud Pharma (Spain), Menadiona Sl (Spain), Rochem International Inc. (US), and Shaanxi Hanjiang Pharmaceutical Group Co. Ltd. (China).
As the demand for veterinary medicines and animal health products continues to rise, the veterinary API market is poised for substantial growth, driven by the increasing prevalence of transboundary and zoonotic diseases, the expanding animal population, and the implementation of improved disease control measures. With the right investments and collaborations, this market has the potential to make significant contributions to animal health and welfare globally.
The global medical display market is experiencing substantial growth, with revenue projected to increase from $2.3 billion in 2023 to $2.9 billion by 2028, reflecting a compound annual growth rate (CAGR) of 5.2%. This expansion is driven by several key factors, including technological advancements, rising demand for diagnostic imaging, increased adoption of minimally invasive procedures, and the surge in telemedicine and remote diagnostics.
One of the primary drivers fueling market growth is the growing adoption of hybrid operating rooms. These advanced facilities are designed to perform sophisticated and minimally invasive surgeries, integrating imaging and surgical tools for improved precision, safety, and procedural outcomes. Consequently, hospitals are replacing outdated display systems with newer, high-resolution medical displays to enhance visualization and facilitate collaboration between surgical and imaging teams.
Download a PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=74058413
However, the market faces a restraint in the form of increasing adoption of refurbished medical displays. Healthcare facilities, particularly smaller ones and those in emerging economies, are turning to refurbished devices as a cost-effective alternative. This trend poses a challenge for market players, who must either lower prices or introduce more advanced technologies to address unmet needs.
Emerging economies present a significant opportunity for the medical display industry. Governments and private players in regions like Asia are making significant investments to modernize healthcare infrastructure and cater to the growing demand for better healthcare services. This investment is expected to drive revenue growth opportunities for market players.
Nevertheless, the adoption of consumer-grade displays in medical settings poses challenges related to image quality, calibration, regulatory compliance, longevity, reliability, and vendor support. Healthcare providers, particularly in developing countries like India and China, are increasingly turning to lower-priced consumer-grade displays, which could impact the growth of the professional medical display market.
The market ecosystem consists of manufacturers engaged in research, product development, optimization, and introduction of medical displays, as well as distributors, including third-party and e-commerce platforms affiliated with these organizations.
Within the market segments, the OLED displays category is expected to witness the fastest growth during the forecast period, as these displays enable healthcare professionals to notice subtle details and color differences that many LED displays lack. Additionally, the diagnostic applications segment accounted for the largest share in 2022, driven by the increasing prevalence of diseases like cancer and the growing number of patients being screened using imaging systems.
Geographically, North America held the largest market share in 2022, owing to factors such as good healthcare infrastructure, increasing demand for diagnostic imaging, technological advancements, and rising adoption of picture archiving and communication systems (PACS).
Key players in the medical display market include Barco NV, Eizo, Sony Electronics Inc., LG Electronics, Novanta, FSN Medical Technologies, Advantech, Quest International, Steris, Jusha Medical, Siemens Healthineers AG, Double Black Imaging, HP Development Co. Ltd, Stryker, and Coje Display.
With the rising demand for advanced healthcare services and the continuous technological advancements in medical imaging, the medical display market is poised for significant growth in the coming years.
The physiotherapy equipment market is rapidly expanding, projected to grow from $18.4 billion in 2022 to $24.5 billion by 2027 at a 6.0% annual rate. Several key drivers are fueling this growth, including the rising elderly population, increasing prevalence of chronic diseases, more sports injuries and degenerative joint disorders, and heightened demand for rehabilitative care. However, unstable reimbursement policies, personnel shortages, and competition from alternative therapies like acupuncture could restrain market expansion.
A major growth driver is the growing need for rehabilitative care to improve strength, mobility and manage conditions like asthma or post-surgery recovery. As healthcare providers integrate rehab into their continuum of care to enhance outcomes and reduce lengths of stay, demand for physiotherapy equipment is increasing.
Download a PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=65250228
Unstable insurance reimbursement creates challenges, with variable coverage leading some patients to face high out-of-pocket costs or visit limits that hinder their progress in therapy. Alternative treatments like acupuncture, offering benefits like low cost and high compliance, provide competition for physiotherapy.
The market landscape is evolving with new technological advances like virtual reality, robotics, exoskeletons and interactive video games creating opportunities for innovation. Leading players like Colfax, Zimmer MedizinSysteme, Zynex, Performance Health and ITO are driving product development.
Colfax Corp. (US) dominated the physiotherapy equipment market in 2021. The company has its business operations in the US, the Asia Pacific, the Middle East, Africa, Germany, Australia, Canada, and Latin America. It maintains its leadership position in this market through its strong distribution network across the globe. Moreover, significant investments in R&D enable the company to provide innovative products and services in this market space, thus maintaining and improving its competitive position in the physiotherapy equipment market.
Zimmer Medizinsysteme GmBH (Germany) is among the leading providers of physiotherapy equipment and is ranked at 2nd position in the physiotherapy equipment market. The company is recognized for its strong distribution network and has a strong customer base, which includes medical professionals, physiotherapists, and movement experts. The company significantly focuses on quality improvements in its products, on-time deliveries, and improving its post-sales services. Zimmer is executing its strategy to grow through a value-driven acquisition program to become a recognized brand in the physiotherapy equipment market. The company intends to provide value to its customers, clinicians, investors, and stakeholders by executing its core strategy of sustained revenue growth and focused business development.
The equipment segment, including electrotherapy, ultrasound and exercise therapy devices, dominates the market. Musculoskeletal applications form the largest clinical segment due to rehab needs for injuries and disorders. Physiotherapy and rehab centers are the biggest end-user category using advanced equipment.
Europe currently leads regional growth driven by countries like Germany, the UK and France, while Asia-Pacific is expected to see the highest future growth rate. Factors like active lifestyles, aging populations, service penetration and healthcare reforms are propelling the European and Asian markets.
The global multiplex assays market is projected to experience robust growth in the coming years, driven by the increasing advantages of multiplex assays over traditional singleplex and conventional assays. According to a new research study, the market was valued at $3.5 billion in 2022 and is expected to reach $5.3 billion by 2027, growing at a compound annual growth rate (CAGR) of 8.8% during the forecast period.
Multiplex assays offer several benefits over conventional methods, including automation, convenience, accuracy, and reproducibility. These assays allow for the simultaneous measurement of multiple analytes in a single sample, reducing the overall cost and time per assay. Bead-based microplate assays, in particular, provide a greater surface area for binding with lower background signals compared to traditional ELISA techniques, and the beads can be coded for use in multiplex assays.
Download a PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=61593314
The increasing focus on the need for high-throughput and automated systems in laboratories is a significant opportunity for the multiplex assays market. The rising pressure for healthcare cost reduction and the growing patient population have highlighted the inadequacy of conventional testing methods, fueling the demand for efficient and automated solutions.
However, the market faces challenges, such as the rising costs of equipment and the increasing dearth of skilled professionals. The initial investment in multiplex assay equipment is high, and the variable costs of reagents, maintenance, and overhead expenses add to the overall expenditure. Additionally, there is a shortage of skilled technicians, as it takes several years of continuous practice to gain expertise in clinical laboratory work.
In terms of product segments, the consumables segment accounted for the largest share of the market in 2022, driven by the recurrent purchase of consumables for research and clinical diagnostic applications. Regarding type, protein multiplex assays held the largest share due to their increased usage for biomarker research and clinical diagnostics.
The pharmaceutical and biotechnology companies segment was the largest end-user segment in 2022, as multiplex assays are widely used in the pharmaceutical industry for clinical pharmacokinetics and bioequivalence studies in drug discovery.
Geographically, North America dominated the multiplex assays market in 2022, accounting for 45.1% of the global market share. The high burden of infections and cancers, well-developed healthcare infrastructure, and growing adoption of advanced technologies for cancer and infectious disease testing are driving market growth in the region.
Key players in the multiplex assays market include Illumina, Inc., Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc., Becton, Dickinson and Company, and DiaSorin S.p.A. These companies lead the market with their extensive product portfolios, wide geographic presence, robust marketing and distribution networks, and substantial budgets for research and development.
The global behavioral health software market is experiencing rapid growth, projected to expand from $2 billion in 2021 to $4.9 billion by 2026 at an impressive 19.6% CAGR. Several factors are fueling this market’s rise, including increasing adoption of such software, government funding availability, initiatives encouraging EHR use in behavioral health organizations, greater focus on high-quality mental health care, favorable U.S. reforms, and soaring demand amidst provider shortages. Key players are actively launching new products, services, and partnerships to drive further market expansion.
Download a PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=45953340
Catalysts for Growth
High treatment costs for mental illnesses are a major government concern globally. Depression alone affects over 264 million people worldwide, with projected global treatment costs skyrocketing from $2.5 trillion in 2020 to $6 trillion by 2030. In the U.S., serious mental illnesses result in $193.2 billion in lost earnings annually. Excessive paperwork, medication errors, and inefficient revenue cycle management contribute to these staggering costs. Behavioral health software offers solutions by reducing paperwork, enhancing clinician productivity, improving workflow, and minimizing healthcare expenses – driving its increased adoption, especially in large hospitals and clinics.
Hurdles to Overcome
Data privacy remains the biggest concern for behavioral health providers bound by regulations like HIPAA restricting sharing of patient information. Despite measures like HIPAA and GDPR, data breaches continue rising, with 183 incidents in the U.S. healthcare sector in 2021 alone. Financial constraints also pose challenges, as behavioral health software solutions are relatively costly with high maintenance and upgrade expenses sometimes exceeding the software price itself.
Opportunities Ahead
Emerging markets in Asia-Pacific, Latin America, and the Middle East & Africa present significant growth potential. Government initiatives establishing standards, regulations and infrastructure in countries like Australia are encouraging healthcare providers to adopt EMR and EHR technology to reduce errors and increase efficiency.
Within the market, the support services segment demanding continuous software upgrades and maintenance is expected to dominate in 2021. Community clinics are projected to be the fastest-growing end-user segment driven by government support and patient preferences. Geographically, North America led by the U.S. will maintain its dominance due to increasing behavioral health services demand, reforms, and government funding in the region.
Major players shaping the landscape include Cerner, Netsmart, AdvancedMD, Credible, Kareo, Nextgen, Qualifacts, Valant and others actively pursuing product innovations, service expansions and strategic collaborations to secure a larger stake.
CERNER (US)
Cerner is the leading player in the behavioral health software market. The company’s expertise, experience, and comprehensive capabilities in various business functions have enabled it to maintain its leading position in this market. The company has a major presence in the US, and approximately 88% of its revenues came from the US in 2020. Its solutions are licensed by ~27,000 facilities worldwide. Cerner has a strong sales and marketing network, with sales offices in 35 countries across the globe. The company focuses on achieving sustainable growth by adopting inorganic growth strategies such as mergers and acquisitions.
NETSMART(US)
Netsmart is the second-leading player in the behavioral health software market. The leading position of the company in this market is attributed to its strong relationship with its customers. The company has a keen focus on building and maintaining strong client relationships to enhance its growth. Additionally, Netsmart focuses on inorganic growth strategies such as acquisitions, partnerships, and collaborations to enhance its presence in this market. In February 2020, Netsmart acquired GPM, a North Carolina-based Software-as-a-Service technology and services company. This will help Netsmart’s CareFabric platform to deliver interoperable data sharing between long-term care facilities and providers. The company‘s client base includes more than 560,000 users and 25,000 organizations across 50 state systems.
QUALIFACTS (US)
Qualifacts is the third-leading player in the behavioral health software market. The company‘s strong customer base is a major reason for its leading position in the market. Qualifacts has a client base of ~50,000 behavioral healthcare providers and ~15,000 clinical personnel. The company has a strong market presence in over 40 states across the US, allowing it to market products effectively and maintain its position in this market.
The global cartilage repair market is experiencing robust growth, projected to expand from $1.3 billion in 2023 to $2.8 billion by 2028, at an impressive compound annual growth rate (CAGR) of 17.2%. This burgeoning market is fueled by several key factors, including the rising prevalence of osteoarthritis worldwide and increasing growth opportunities in emerging economies.
A Mounting Osteoarthritis Burden
Osteoarthritis, a debilitating condition characterized by the degeneration of cartilage in joints, has emerged as a significant driver of the cartilage repair market. According to the World Health Organization, in 2019, an estimated 528 million people worldwide were living with osteoarthritis, a staggering 113% increase since 1990. Furthermore, a recent study published in The Lancet revealed that a concerning 15% of the global population over the age of 30 suffers from this condition.
As the population ages and obesity rates continue to rise, the burden of osteoarthritis is expected to escalate further. By 2050, nearly 1 billion individuals are projected to be affected by this debilitating condition. Consequently, the demand for effective cartilage repair and regeneration products, such as autologous chondrocyte implantation and scaffold implants, is anticipated to surge.
Download a PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=37493272
Technological Advancements Pave the Way
The cartilage repair market is also benefiting from continuous technological advancements in the field. Ongoing research and development efforts are focused on identifying universal sources of progenitor cells, such as embryonic and induced pluripotent stem cells, for cartilage regeneration. While challenges like immune rejection, tumorigenesis, and teratoma formation remain, regulatory bodies like the Human Tissue Authority (HTA), Human Fertilization and Embryology Authority (HFEA), Medicines and Healthcare Products Regulatory Agency (MHRA), and the Central Ethics Committee for Stem Cell Research are working to ensure the safe and ethical use of these technologies.
Key Market Segments and Regional Dynamics
The cartilage repair market is segmented based on various factors, including treatment modalities, applications, and application sites. In 2022, the hyaline cartilage segment experienced the highest growth rate, driven by an increasing number of contracts and agreements between key market players, as well as rising investments in research and development of tissue-engineered products for cartilage injury or damage treatment.
Geographically, North America dominates the cartilage repair market, primarily due to the high prevalence of knee-related conditions and the subsequent demand for knee arthroscopy procedures. Major players in the market include industry giants such as Smith+Nephew (UK), DePuy Synthes (Johnson & Johnson) (US), Zimmer Biomet Holdings, Inc. (US), Stryker Corporation (US), and Vericel Corporation (US).
Challenges and Opportunities
While the cartilage repair market presents significant growth opportunities, it is not without its challenges. One notable barrier is the high cost of cartilage repair surgeries, which can range from $18,000 to $23,000, significantly higher than the average cost of a total knee replacement surgery ($16,000). This cost factor may limit the adoption of cartilage repair procedures, particularly in developing countries with limited healthcare resources.
However, the market also presents attractive opportunities for growth, driven by technological advancements and the development of innovative cartilage repair solutions. As research progresses and costs potentially decrease, the cartilage repair market is poised to experience substantial growth, offering hope for millions of individuals suffering from osteoarthritis and other cartilage-related conditions.
The global glycated albumin assay market is projected to experience robust growth in the coming years, escalating from $0.2 billion in 2023 to $0.3 billion by 2028. This upward trajectory, with a projected compound annual growth rate (CAGR) of 8.9%, can be attributed to several key driving forces.
Foremost among these is the alarming rise in the prevalence of diabetes worldwide. As this chronic metabolic disorder becomes increasingly widespread, the demand for accurate diagnostic tools, such as glycated albumin assays, is experiencing a corresponding surge. These assays play a crucial role in monitoring and managing diabetes by measuring the glycated portion of albumin in the blood, providing valuable insights into long-term glycemic control.
Download a PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=265553363
Additionally, governmental initiatives aimed at promoting disease diagnosis and raising awareness about diabetes management are contributing to the market’s expansion. As public health campaigns highlight the importance of early detection and effective treatment, the utilization of glycated albumin assays is poised to increase substantially.
However, the market’s growth is not without its challenges. One significant hurdle is the unfavorable reimbursement landscape, with inadequate coverage from Medicare and private health insurers failing to fully reflect the actual cost and clinical value of these diagnostic tests. This financial barrier could impede the widespread adoption of glycated albumin assays, necessitating concerted efforts to address reimbursement policies.
On a positive note, the market is expected to benefit from the rising investments in healthcare and life sciences research, particularly in emerging economies such as India, South Korea, Brazil, and Mexico. These regions, characterized by high disease prevalence, substantial patient populations, and improving healthcare infrastructure, present lucrative opportunities for the glycated albumin assay industry.
Concurrently, navigating the evolving regulatory landscape poses a formidable challenge. Stringent legal requirements and increasing scrutiny from regulatory bodies, such as the US Food and Drug Administration (FDA) and the European Union (EU), demand continuous adaptation and compliance from manufacturers. Failure to meet these standards could impede market growth and hinder the introduction of innovative diagnostic solutions.
Looking ahead, the glycated albumin assay market is poised for substantial growth, driven by the escalating demand for effective diabetes management tools and supported by favorable demographic trends. However, addressing the reimbursement conundrum and navigating the intricate regulatory environment will be crucial for unlocking the market’s full potential and ensuring widespread access to these essential diagnostic tests.
In 2022, Asahi Kasei Corporation (Japan) led the glycated albumin assay market. The company has maintained a leading position in the market through its strong presence worldwide. The company partners with third parties to offer integrated solutions. The company’s strategy focuses on four factors: affordability, capacity, outcome certainty, and values. The firm implements tailored pricing solutions to ensure maximum patient access. The company also focuses on developing new pricing models for its customers. Additionally, Asahei strategically invests in R&D to strengthen its position in the market. For instance, the company’s R&D expenditure accounted for USD 5.1 billion in 2022. This rise in R&D spending indicates the company’s growing focus on innovation and diversification in emerging markets.
In 2022, Beijing Strong Biotechnologies, Inc. (China) was the second-largest market player in the glycated albumin assay ecosystem. It has an increased presence in Asia Pacific with a strong network and growth strategies and has a product portfolio in the glycated albumin assay market. The company focuses on increasing R&D with increased investment in innovation.
The global mass spectrometry market is witnessing robust growth, driven by increasing research and development investments in the pharmaceutical and biotechnology sectors. Valued at $5.4 billion in 2023, this market is projected to reach $7.8 billion by 2028, expanding at an impressive compound annual growth rate (CAGR) of 7.5%.
Mass spectrometry plays a crucial role in drug discovery and development processes, from early-stage research to clinical trials. As pharmaceutical companies continue to invest in biopharmaceuticals and personalized medicine, the demand for mass spectrometry instruments and services is expected to surge.
Download a PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=437
While premium pricing for these advanced systems remains a restraint, emerging economies like China and India present lucrative growth opportunities. The flourishing biopharmaceutical industries in these countries are fueling the demand for mass spectrometers and hybrid spectrometry instruments.
However, the market faces a significant challenge in the form of a skilled workforce shortage. Efficient operation and troubleshooting of mass spectrometry equipment require specialized expertise, which is currently in limited supply.
The market is segmented based on products, sample preparation techniques, applications, and end-users. The hybrid mass spectrometry segment dominates the product category, while liquid chromatography-mass spectrometry (LC-MS) leads in sample preparation techniques due to its high sensitivity and minimal sample preparation requirements.
The OMICS research segment, encompassing genomics, proteomics, and metabolomics, is expected to witness substantial growth during the forecast period, driven by advancements in diagnostics and biomarker identification.
Regionally, North America currently holds the largest market share, fueled by robust funding for research, government initiatives, and widespread usage in sectors like metabolomics and petroleum.
Key players in the mass spectrometry market include SCIEX AB, Thermo Fisher Scientific, Agilent Technologies, Waters Corporation, PerkinElmer Inc., Shimadzu Corporation, Bruker Corporation, Analytik Jena, JEOL Ltd., Hiden Analytical, and MKS Instruments, among others.
Thermo Fisher Scientific (US)
Thermo Fisher is a US-based company that offers a complete and integrated portfolio of solutions and services for laboratory research & analysis, healthcare & clinical science, manufacturing, and other fields. The company operates through four business segments, namely, Analytical Instruments, Life Sciences Solutions, Specialty Diagnostics, and Laboratory Products & Services. The Analytical Instruments business segment offers mass spectrometry products. Thermo Fisher being a major player can be attributed to its extensive portfolio of mass spectrometry equipment used for various applications. It focuses on expanding its product portfolio by introducing new and advanced mass spectrometers for customers in biotechnology, pharmaceuticals, toxicology, forensics, and other fields. In 2021, the company launched new mass spectrometry software, MAM 2.0 workflow and Orbitrap Exploris MX mass detector. Thermo Fisher Scientific also engages in collaborations and agreements for growth.
SCIEX (US)
SCIEX, a US-based scientific instrumentation provider, is another major player in the mass spectrometry market. The company provides an elaborate portfolio of liquid chromatography-mass spectrometry instruments & accessories for life science, clinical research, and industrial markets. The company provides products mainly targeted at environmental testing, especially water analysis. It has focused on organic & inorganic growth strategies, including product launches, collaborations, and partnerships. Also, in 2021, the company built a new category of analytical instrumentation with icIEF-MS in collaboration with customer partnerships, which can help SCIEX gain an advantage over its competitors
Agilent Technologies (US)
Agilent Technologies provides a comprehensive portfolio of LC-MS, GC-MS, and ICP-MS in the mass spectrometry market. The company has a strong presence in North America and Europe. Over the last few years, the company has increased its R&D activities with a focus on investing a significant amount of its revenue in R&D; and will continue to have significant research and development expenditures in order to maintain the competitive position with a continuing flow of innovative, high-quality products and services. The company is also focusing on acquisitions, collaborations, and expansions to maintain its position in the market. For instance, in 2018, Agilent acquired its related business from Young In Scientific Co. Ltd. (a distributor of analytical and scientific instruments in South Korea), which helped it expand its presence in the South Korean market. Agilent’s mass spectrometers are reasonably priced in comparison to its competitors.
As the pharmaceutical and biotechnology industries continue to evolve, the mass spectrometry market is poised for significant growth, driven by technological advancements, emerging applications, and increasing demand from both developed and emerging economies.
The global epigenetics market is witnessing remarkable growth, poised to surge from $1.8 billion in 2023 to an impressive $4.3 billion by 2028, reflecting a robust compound annual growth rate (CAGR) of 18.3%. This burgeoning market is fueled by favorable government initiatives, substantial investment in epigenetic research, and an escalating demand for epigenetic-based therapeutics.
At the heart of this growth lies the quest to unravel the intricate mechanisms governing gene expression and its pivotal role in a myriad of diseases, ranging from cancer and neurological disorders to autoimmune conditions. Pharmaceutical and biotechnology giants are channeling substantial resources to decipher the complexities of epigenetic processes, harnessing their therapeutic potential to revolutionize treatment paradigms.
Download a PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=896
Notable players in this arena include industry titans such as Thermo Fisher Scientific, Illumina, PacBio, Abcam, Merck KGaA, and Bio-Rad Laboratories, among others. Their relentless pursuit of innovation is driving the integration of cutting-edge technologies, including artificial intelligence (AI) and machine learning (ML) algorithms, to unlock unprecedented insights into epigenetic patterns and their implications for disease prevention and management.
Illumina Inc (US)
In 2022 Illumina, Inc. (US) held a dominant position in the market. has successfully established a robust customer base encompassing pharmaceutical and biotechnology firms, genomic research centers, and government laboratories and hospitals. Moreover, the company enjoys a monopoly in the NGS market, providing a strategic advantage for venturing into adjacent markets such as epigenetic sequencing. For instance in 2022, Illumina, Inc. entered into an agreement with SomaLogic (US) to introduce SomaScan Proteomics Assay in high throughput next-generation sequencing (NGS) platforms manufactured by Illumina.
Thermofisher Scientific Inc (US)
Thermo Fisher Scientific (US) held the leading position in the market in 2022. The company has Strong brand image along with the diverse product portfolio. For instance in 2022, thermofisher launched the CE IVD Marked Next Generation Sequencing Instrument designed to be used in in clinical laboratories to perform both diagnostic testing and clinical research on a single instrument.
Merck KgaA (Germany)
Merck KGaA (Germany) is also one of the key player in the epigenetics market. The Life Science Research business segment of the company contributes over 45% to its 2022 revenue by providing a variety of epigenetics assays and kits. These offerings include assays for comprehensive genome-wide DNA methylation assessment as well as targeted evaluation at specific loci.
While the epigenetics market holds immense promise, it is not without its challenges. Quality concerns surrounding antibodies, the backbone of epigenetic research, pose a significant obstacle. Issues such as cross-reactivity, inconsistent sensitivity, and reproducibility threaten to undermine the accuracy and reliability of findings. Additionally, the absence of standardized validation protocols and the limited availability of well-validated antibodies for emerging epigenetic markers compound these challenges.
Nevertheless, the epigenetics market remains resilient, buoyed by the potential for transformative discoveries and driven by the relentless pursuit of knowledge. As we delve deeper into nature’s intricate code, the epigenetics revolution promises to reshape our understanding of health, disease, and the very fabric of life itself.